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Abstract
Background: Creating an easy-to-use instrument to identify predictors of short-term (30/60-day) mortality after
an exacerbation of chronic obstructive pulmonary disease (eCOPD) could help clinicians choose specific measures
of medical care to decrease mortality in these patients. The objective of this study was to develop and validate a
classification and regression tree (CART) to predict short term mortality among patients evaluated in an emergency
department (ED) for an eCOPD.
Methods: We conducted a prospective cohort study including participants from 16 hospitals in Spain. COPD patients
with an exacerbation attending the emergency department (ED) of any of the hospitals between June 2008 and
September 2010 were recruited. Patients were randomly divided into derivation (50 %) and validation samples
(50 %). A CART based on a recursive partitioning algorithm was created in the derivation sample and applied to
the validation sample.
Results: Two thousand four hundred eighty-seven patients, 1252 patients in the derivation sample and 1235 in
the validation sample, were enrolled in the study. Based on the results of the univariate analysis, five variables
(baseline dyspnea, cardiac disease, the presence of paradoxical breathing or use of accessory inspiratory muscles,
age, and Glasgow Coma Scale score) were used to build the CART. Mortality rates 30 days after discharge ranged
from 0 % to 55 % in the five CART classes. The lowest mortality rate was for the branch composed of low baseline
dyspnea and lack of cardiac disease. The highest mortality rate was in the branch with the highest baseline dyspnea
level, use of accessory inspiratory muscles or paradoxical breathing upon ED arrival, and Glasgow score <15. The area
under the receiver-operating curve (AUC) in the derivation sample was 0.835 (95 % CI: 0.783, 0.888) and 0.794 (95 % CI:
0.723, 0.865) in the validation sample. CART was improved to predict 60-days mortality risk by adding the Charlson
Comorbidity Index, reaching an AUC in the derivation sample of 0.817 (95 % CI: 0.776, 0.859) and 0.770 (95 % CI: 0.716,
0.823) in the validation sample.
Conclusions: We identified several easy-to-determine variables that allow clinicians to classify eCOPD patients by short
term mortality risk, which can provide useful information for establishing appropriate clinical care.
Trial registration: NCT02434536.
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Background
Outcomes as long-term mortality and short-term mortality
are frequently used in studies of mortality following
hospitalization for an exacerbation of COPD (eCOPD)
[1, 2]. In long-term follow-up, mortality is likely more
influenced by the general characteristics of the pa-
tient’s COPD than the severity of the eCOPD that trig-
gered the admission. Short-term mortality, usually
defined as mortality occurring less than 90 days after
presentation to a hospital with an eCOPD, usually in-
cludes in-hospital mortality, and factors related to the
severity of the exacerbation likely play more important
role in the short term rather than in the mid or long
term follow-up.
CART models have been used in various disciplines
and diseases [3, 4]. CART analysis has also been used to
predict 5-year mortality among patients with stable
COPD using five easily obtained parameters in clinical
practice with good predictive capacity compared to other
prognostic multidimensional based instruments [5].
CART has also been used to predict short-term or long-
term mortality and the need for mechanical ventilation
among patients with acute exacerbations of COPD [6].
Many studies evaluating short-term outcomes in
eCOPD patients have focused on the 90-day period fol-
lowing the episode. We focused on a shorter period after
the index event (30/60 days) in an effort to find factors
more closely related to the eCOPD event and differences
in predictive factors for both mortality periods. Few
studies have taken this approach, even though important
outcomes such as mortality and readmissions occur
during this period. The aim of our study was to develop
and validate a CART to predict 30 and 60-days mortality
following an emergency department (ED) evaluation for
an eCOPD. Identifying factors related to mortality during
this period could provide valuable information about the
appropriate clinical care for these patients.
Methods
We used data collected as part of the Investigacion en
Resultados y Servicios de Salud COPD Appropriateness
(IRYSS-COPD) for this investigation. Methods of the
IRYSS-COPD Study have been described in detail else-
where [7]. In brief, this prospective cohort study
included patients with an eCOPD attending the emer-
gency departments (ED) of 16 hospitals in Spain
between June 2008 and September 2010. All patients
were informed of the goals of the study and invited to
voluntarily participate in it. Patients who agreed to
participate provided written consent. All information
was kept confidential.
Patients were eligible for the study if they presented to
the ED with symptoms consistent of an eCOPD. COPD
was confirmed if the patient had a forced expiratory
volume in 1 second/forced vital capacity (FEV1/FVC)
quotient <70 %. Exacerbation was defined as an event in
the natural course of a patient’s COPD characterized by
a change in baseline dyspnea, cough, and/or sputum that
was beyond normal day-to-day variations and that may
have warranted a change in medication or treatment [8].
For patients already known to have been diagnosed of
COPD, the closest sprirometry data to the ED index visit
performed at a time when the patient was stable, and
not longer than 6 months, was taken as reference. When
COPD was newly diagnosed during the ED visit, to be
included in the study, the patient had to have COPD
confirmed by spirometry within 60 days after the index
episode at a time when he or she was stable [9]. In those
cases, that spirometry was taken as reference. No
spirometry data was recorded from the ED nor during
the admission to the hospital.
Gold [9] patients were excluded from the study if, at
the time they were seen in the ED, the eCOPD was com-
plicated by a comorbidity such as pneumonia, pneumo-
thorax, pulmonary embolism, lung cancer, or left cardiac
failure. Other exclusion criteria included a diagnosis of
asthma, extensive bronchiectasis, sequelae of tubercu-
losis, pleural thickening, or restrictive diseases. Patients
who did not wish to participate were also excluded.
Data collected
Data collected upon arrival in the ED included socioeco-
nomic information, clinical data at baseline, presence of
pathologies recorded in the Charlson Comorbidity Index
[10], and information about the eCOPD event such as
arterial blood gases, respiratory rate, dyspnea and
consciousness level measured by the Glasgow Coma
Scale [11].
For patients admitted to the hospital, we collected
additional data from the medical record and from a
direct interview with the patient on the first day after
admission and also on the day of discharge. We asked
all patients to tell us about their physical activity, general
health, and dyspnea level when they were in a stable
condition before the eCOPD and 24 hours after being
admitted to the hospital or discharged from the ED to
home. We used the Medical Research Council (MRC)
breathlessness scale [12] to measure baseline dyspnea.
For all patients with known COPD, additional vari-
ables collected from medical records included baseline
severity of COPD as measured by FEV1; hospital admis-
sions for eCOPD during the previous 12 months; base-
line therapy and the presence of conditions needed to
determine the Charlson Comorbidity Index.
Reviewers were trained to identify pertinent data and a
precise manual was developed to help reviewers collect
the data.
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Mortality at 30/60 days after the index ED index was
determined by consulting medical records, regional elec-
tronic databases and the national registry of mortality.
Statistical analysis
The outcomes variables were defined as mortality within
30 days or 60 days of the index ED visit for the eCOPD.
Patients were randomly divided into a derivation sample
(50 %) and a validation sample (50 %). Derivations sam-
ple was used in order to develop the CART, whereas
validation sample was used to validate the results ob-
tained from the previously derived CART. Both samples
were described using means and the standard deviations
for continuous variables and the number of cases and
percentages for categorical variables. Differences be-
tween the derivation and the validation samples were
tested for the distribution of each variable using the t-
test for continuous variables and the chi-square test for
categorical variables. Missing data on baseline level of
dyspnea (MRC breathlessness scale) were considered as
a separate category from other data. Justification for the
inclusion of missing dyspnea data was based on the fact
that patients without a measurement of baseline dys-
pnea were significantly different from patients with
lower levels of breathlessness (MRC categories 1 to 4
[p < 0.0001]) but not from those with the most severe
breathlessness (MRC category 5 [p = 0.63]).
A CART based on a recursive partitioning algo-
rithm was created in the derivation sample [13] to
identify 30-day mortality risk factors with the highest
discriminative power. The goal was to identify the
variables and partition point that optimally separate low-
risk patients from high-risk patients. To internally validate
the risk of 30-day mortality derived from the regression
tree, we used bootstrap resampling with N = 2,000 repeti-
tions and estimated 95 % confidence intervals (95 % CI)
[14]. We report the median of these 2,000 repetitions as
the parameter estimate and the 2.5 and 97.5 percentiles as
the 95 % CIs.
To make the CART more user friendly, we simplified
the resulting algorithm into a manageable number of
risk classes based mainly on the estimated risk of 30-day
mortality. We applied the risk classification derived from
the derivation sample to the validation sample. The
Cochran-Armitage trending statistic was performed to
assess whether classification provided by the CART
could differentiate low-risk patients from high-risk pa-
tients in a fashion of graded response based on the level
of risk present.
The 30-day mortality derived and validated classifica-
tion tree was applied to 60-day mortality. Additional
variables to improve the 30-day mortality risk prediction
to 60-day mortality risk prediction were selected from
the univariate analysis and added to the CART analysis
in order to get the best prediction tree for 60-day
mortality.
Model discrimination of the trees and the risk categories
was assessed by the area under the receiver operating
curves (AUC).
Effects were considered statistically significant at α =
0.05. All statistical analyses were performed using SAS
for Windows© version 9.1, except for the development
and validation of the regression tree, which was built
using R version 2.14.
Results
A total of 2487 patients were enrolled in the study.
(Figure 1) they were divided into the derivation sample
(1252 patients) and the validation sample (1235 pa-
tients). The only difference between the two samples
was use of accessory inspiratory muscles at ED admis-
sion, which was higher in the derivation sample (more
information in Additional file 1: eTable S1).
Factors associated with mortality are shown in Table 1.
Based on results of the univariate analysis, we included
these significant variables in the splitting process of
building the classification tree for 30-day mortality: the
MRC baseline dyspnea scale, cardiac disease, presence of
UAIM or PB at ED admission, age, and Glasgow Coma
Scale score. The CART created for 30-day mortality with
data from the derivation cohort is shown in Fig. 2. No
patients with a low level of dyspnea at baseline (MRC
breathlessness level 1–2) and without cardiac disease
died in the 30-day follow-up period. In contrast, 55 % of
patients with the most extreme baseline dyspnea (MRC
breathlessness level 5), UAIM/PB at ED admission,
and a Glasgow Coma Scale score <15 died during the
30-day follow-up period. Among patients with MRC
level 5 dyspnea at baseline, those without UAIM/PB
who were less than 75 years old had a mortality rate
of 4 %. The AUC in the derivation sample was 0.835
(95 % CI: 0.783, 0.888) and 0.794 (95 % CI: 0.723,
0.865) in the validation sample.
When applied the original 30 days mortality CART to
60 days mortality the AUC was 0.774, (95 % CI: 0.723,
0.826) in the derivation and 0.73, (95 % CI: 0.671, 0.790)
in the validation sample. The Charlson Comorbidity
Index (>2/<=2) was identified as the only significant
variable that added to that the 30-days tree increases the
CART prediction for mortality risk at 60-days (Fig. 3).
Then, the AUC in the derivation sample improves to
0.817 (95 % CI: 0.776, 0.859) and to 0.770 (95 % CI:
0.716, 0.823) in the validation sample.
Using data from the derivation sample, the CART tree
created four short-term mortality risk classes. This risk
classification was validated in the validation (Table 2).
The Cochran-Armitage test showed a statistically signifi-
cant trend in both samples (p < 0.0001). Risk classes
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were also established and validated for 60 days mortality.
Though heart rate was flagged as a predictor by some of
the CART models, the use of UAIM/PB provided more
reliable data. Additional analysis showed that heart rate
and UAIM were correlated. Patients without cardiac dis-
ease and without UAIM/PB at ED evaluation had a
mean heart rate of 93.3 (17.9) compared to a mean heart
rate of 102.1 (21.4; p = 0.0005) among those who demon-
strated UAIM/PB at ED evaluation.
More detailed results on internal bootstrap validation
are shown in Additional file 1: eFigure S1 and Additional
file 1: eTable S2. AUC for the CARTs decision trees in
the derivation and validation samples for both mortality
outcomes are presented in Fig. 4.
Discussion
Dyspnea at baseline was the main variable associated
with 30-day mortality after an ED evaluation for eCOPD.
It provided the first branch of the CART. The next
branches included the presence of cardiac disease, age,
UAIM/PB, and the Glasgow Coma Scale score.
In our cohort, 3.6 % of patients died within 30 days of
the index eCOPD. In similar studies, mortality during
this period was 1 % [15] and 2.1 % [16]. At 60-day after
the event mortality rate almost doubled the rate.
The variable that established separation in the first
branch of the CART was baseline dyspnea. Among
patients with stable COPD, dyspnea has been identified
as a more important prognostic factor than pulmonary
function (FEV1) [17, 18]. In two studies of in-hospital
mortality among eCOPD patients, baseline dyspnea was
independently associated with mortality [19, 20]. In con-
trast, a study evaluating long-term mortality (4 years)
following hospitalization for an eCOPD found that dys-
pnea at baseline was associated with mortality in the
univariate analysis but not in the multivariate analysis
[21]. Therefore one variable reflecting patients’ baseline
situation, dyspnea, was a very important predictor of in-
hospital and very short-term mortality after an eCOPD
requiring hospital evaluation. In our study, patients with
a level 5 on the MRC breathlessness scale had higher
mortality (18 %–55 % depending on the absence or
presence of neurological impairment). In contrast, pa-
tients with level 1–2 dyspnea at baseline had low rates
of mortality (0 %–2 %).
Cardiac comorbidity was the second-level key factor in
the CART. In analyzing mortality 90 days after discharge
for an eCOPD, Almagro et al. identified age, FEV1
according the GOLD classification, number of previous
hospitalizations for COPD, use of home oxygen therapy,
higher functional dependence, and comorbidities according
Fig. 1 Flow-chart of the sample
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Charlson comorbidity index as factors related to mor-
tality [22]. In our study, cardiac diseases had a greater
impact on 30-day mortality than comorbidities in general.
Donaldson et al. showed that in a short period of time
(1–5 days) after an eCOPD treated with antibiotics and
systemic steroids, the risk of myocardial infarction
significantly increased [23]. In our cohort, 2 % of
patients with little breathlessness at baseline (MRC
levels of 1–2) and cardiac disease died within 30 days
compared to 0 % who did not have cardiac disease. A
similar pattern was seen among patients with more severe
breathlessness (MRC level 3–4), with mortality rates of
5 % among those with cardiac disease and 1 % among
those without it. Cardiac disease and COPD share
Table 1 Univariate analysis performed in the derivation sample (n = 1252)
30-day mortality 60-day mortality
No Yes No Yes
1206 (96.3 %) 46 (3.7 %) 1173 (93.7 %) 79 (6.3 %)
Agea 72.5 (9.8) 77.7 (8.6)* 72.3 (9.8) 77.3 (8.9)*
Sex (Male) 1105 (91.6) 42 (91.3) 1075 (91.7) 72 (91.1)
Baseline FEV1 % **
≥50 42 (4.2) 0 (−) 40 (4.1) 2 (3.0)
30 < FEV1 % < 50 295 (29.4) 6 (14.6) 286 (29.2) 15 (22.7)
≤30 666 (66.4) 35 (85.4) 652 (66.7) 49 (74.2)
Charlson Comorbidity Indexa 2.22 (1.52) 3.11 (2.23)* 2.19 (1.50) 3.15 (2.00)*
>2 374 (31.0) 24 (52.2)** 351 (29.9) 47 (59.5)*
Diabetes mellitus 238 (19.8) 19 (41.3)* 230 (19.7) 27 (34.2)**
Cardiopathy 345 (28.6) 24 (52.2)** 327 (27.9) 42 (53.2)*
Previous LT-DOT or NIMV at home 380 (31.5) 34 (73.9)* 367 (31.3) 47 (59.5)*
Number of previous admissions due to eCOPD 0.85 (1.38) 1.04 (1.28) 0.84 (1.38) 1.08 (1.37)
0-1 970 (80.4) 35 (76.1) 445 (80.6) 60 (76.0)
2 103 (8.5) 2 (4.4) 101 (8.6) 4 (5.1)
≥3 133 (11.0) 9 (19.6) 127 (10.8) 15 (19.0)
Glasgow Coma Score – <15 32 (2.7) 7 (15.2)* 30 (2.6) 9 (11.4)*
Heart rate upon ED arrival (≥120) 104 (8.6) 8 (17.4) 99 (8.4) 13 (16.5)
Use of inspiratory accessory muscle upon ED arrival 256 (21.2) 23 (50.0)* 252 (21.5) 27 (34.2)**
Paradoxical breathing upon ED arrival 52 (4.3) 9 (19.6)* 48 (4.1) 13 (16.5)*
pH upon ED arrival * **
≥7.35 986 (88.6) 30 (68.2) 958 (88.4) 58 (79.5)
7.26-7.34 106 (9.5) 8 (18.2) 105 (9.7) 9 (12.3)
<7.26 21 (1.9) 6 (13.6) 21 (1.9) 6 (8.2)
PCO2 upon ED arrival * *
≤45 613 (58.5) 10 (23.3) 596 (58.4) 27 (38.0)
46-55 233 (22.2) 14 (32.6) 226 (22.2) 21 (29.6)
56-65 111 (10.6) 9 (20.9) 109 (10.7) 11 (15.5)
>65 91 (8.7) 10 (23.3) 89 (8.7) 12 (16.9)
MRC breathlessness scale * *
1-2 404 (33.5) 2 (4.4) 401 (34.2) 5 (6.3)
3 227 (18.8) 3 (6.5) 220 (18.8) 10 (12.7)
4 329 (27.3) 11 (23.9) 319 (27.2) 21 (26.6)
5 119 (9.9) 19 (41.3) 109 (9.3) 29 (36.7)
missing 127 (10.5) 11 (23.9) 124 (10.6) 14 (17.8)
aRepresented as mean (sd)
Statistically significant differences between deceased and not deceased patients at each period of time for each characteristic are shown, *stands for p < 0,001
and **stands for 0.05 < p < 0.001
Esteban et al. Respiratory Research  (2015) 16:151 Page 5 of 10
Fig. 2 Results of the CART analysis for 30-day mortality in the derivation sample. Application to the validation sample is shown below each node
in dashed boxes. Each node shows the classification variable plus the number of subjects and the estimated probability of 30-day mortality on
that node. Estimated one-month mortality risk has been categorized in low, medium, high and very high as show below the tree. Dashed vertical
line shows the cut-off point for dichotomization of estimated mortality risk looking for optimal sensitivity-specificity combination in the derivation
sample, leading to a sensitivity of 0.651 and a specificity of 0.848. UIAM = Use of inspiratory accessory muscle; PB = Paradoxical breathing;
MRC = MRC breathlessness scale
Fig. 3 CART model for 60-day mortality in the derivation sample. Application to the validation sample is shown below each node in dashed
boxes. Each node shows the classification variable plus the number of subjects and the estimated probability of 60-day mortality on that node.
Estimated 60-day mortality risk has been categorized in low, medium, high and very high as show below the tree. Dashed vertical line shows
the cut-off point for dichotomization of estimated mortality risk looking for optimal sensitivity-specificity combination in the derivation
sample, leading to a sensitivity of 0.662 and a specificity of 0.823. UIAM = Use of inspiratory accessory muscle; PB = Paradoxical breathing;
MRC = MRC breathlessness scale; CCI = Charlson Comorbidity Index
Esteban et al. Respiratory Research  (2015) 16:151 Page 6 of 10
smoking and low-grade chronic inflammation as potential
factors that could explain their coexistence.
In a prospective study of patients admitted for an
eCOPD, 10 % had increases in their troponin T levels
[24]. In this group, even a modest increase in this bio-
marker was associated with an increase in long-term
mortality, especially in the first year after the episode
[24]. The mortality rate increases further when troponin
T elevations are associated with tachycardia (>100
beats/min) [25]. Thirty-day mortality among patients
hospitalized for an eCOPD has also been independently
associated with elevated levels of NT-proBNP or troponin
T; when both NT-proBNP and troponin T were elevated,
mortality was 15-fold higher than among patients with
normal values [26].
The design of our study did not modify the usual clinical
practice, so troponin T and NT-proBNP were measured at
the discretion of the treating clinician. Thus, we were not
able to measure the impact of these markers.
Roche et al. [19], using a similar study as ours but
focused on in-hospital mortality, established a model
that included age, baseline dyspnea, and a severity index
that include UAIM and neurological impairment. This
model is very similar to the variables included in our
CART. However, there are some differences. First, our
CART included cardiac disease as a key comorbidity in
the final outcome. Second, the variables included in our
Table 2 Distribution of subjects by estimated 30/60-day
mortality and stratified risk group in both samples
Derivation sample (1252) Validation sample (1235)
30-day mortality
Risk group (Fig. 1) No (1206) Yes (36) No (1193) Yes (42)
Low 785 (99.1) 7 (0.9) 769 (98.7) 10 (1.3)
— — — — —
Medium 218 (96.0) 9 (4.0) 243 (97.2) 7 (2.8)
High 146 (91.8) 13 (8.2) 135 (93.1) 10 (6.9)
Very high 57 (77.0) 17 (23.0) 46 (75.4) 15 (24.6)
AUC 0.808 (0.742 – 0.873) 0.767 (0.686 – 0.847)
60-day mortality
Risk group (Fig. 2) No (1173) Yes (79) No (1159) Yes (76)
Low 515 (99.4) 3 (0.6) 507 (98.4) 8 (1.6)
Medium 183 (96.8) 6 (3.2) 160 (94.7) 9 (5.3)
— — — — —
High 387 (90.6) 40 (9.4) 424 (92.8) 33 (7.2)
Very high 88 (74.6) 30 (25.4) 68 (72.3) 26 (27.7)
AUC 0.798 (0.757 – 0.838) 0.744 (0.691 – 0.898)
Dashed horizontal lines shows the cut-off points for dichotomization of estimated
mortality risk looking for optimal sensitivity-specificity combination in the
derivation sample, leading to a sensitivity of 0.651 and a specificity of
0.848 for 30-day mortality risk and a sensitivity of 0.662 and a specificity
of 0.823 for 60-day mortality risk
Fig. 4 Roc curve for risk 30-day (a) and 60-day (b) mortality predicted by the CART analyses. Solid line applies for derivation sample and dashed
line applies for validation sample. The cut-off point of estimated risk dichotomization for optimal sensitivity-specificity combination for derivation
sample is shown in grey with the corresponding sensitivity and specificity values. a 30-day mortality: AUC = 0.835 and 95 % confidence interval is
(0.783, 0.888) for derivation sample and AUC = 0.794 and 95 % confidence interval is (0.723, 0.865) for validation sample. b 60-day mortality: AUC
= 0.817 and 95 % confidence interval is (0.776, 0.859) for derivation sample and AUC = 0.770 and 95 % confidence interval is (0.716, 0.823) for
validation sample
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CART did not affect every patient. In fact, neurologic
impairment (Glasgow Coma Scale score <15) was in-
cluded in only one branch which, added to the UAIM/
PB and with a dyspnea grade of 5, was associated with
the highest mortality rate of the whole cohort, 55 %.
A low Glasgow Coma Scale score has been associated
with increased mortality in ICU-admitted eCOPD pa-
tients [27], but not in short-term (30-day) follow-up.
Variables such as severity of airway obstruction and
previous hospitalizations for eCOPD have been cited as
factors related to eCOPD mortality. In our study,
though, they were not identified as prognostic variables
for 30-day mortality following ED evaluation for an
eCOPD.
Once the CART developed for 30-day mortality risk
prediction was applied to 60-day mortality risk predic-
tion predictive ability decreases. However, a new variable
took a relevant role in almost every branch of the deci-
sion tree, number of comorbidities as measured by the
Charlson Comorbidity–index, improving the predictive
ability of the tree for 60-day mortality risk prediction.
Comorbidities have been considered an important mor-
tality predicting factor [22] even has been included in
some multidimensional prognosis index. [16, 28] This
implies that factors related to mortality after such a
hospitalization change in a short -time, reaching pro-
gressively more importance some aspect of the general
clinical condition of the patient as comorbidities are.
This is a key issue when considering the global treat-
ment and follow-up for these patients.
Our decision tree was built by recursive partitioning
using CART. One important advantage of CART over
linear and additive models is that it does not require
parametric specification of the nature of the relationship
between predictors and outcome. In practice, this means
that the assumption of linearity, which is frequently
made in conventional regression models, is not required.
In addition, the CART method allows for naturally in-
corporating interactions between predictors beyond
what had previously been known, and these predictors
can be easily interpreted by researchers.
These results highlight the ease with which CART
models incorporate complex interactions. The interac-
tions describe above would not have been detected by
regression models, even with large sample sizes as the
one in our study. Our CART was developed with 46
events and 5 predictors. When developing clinical pre-
diction models with a binary outcome, a recommended
sample size of 10 events per predictor is an extended
rule [29–31]. Moreover, the internal validation of the
CART provided by the bootstrap analysis showed that
the results were very stable even with less than 4 % of
events in the sample. In addition, CART models can
handle missing values in a more natural way than more
traditional techniques, in which subjects with missing
values are eliminated from the analysis. In our decision
tree, a clinician can extrapolate the likely mortality risk
for a patient with missing information.
Our study has several strengths. The large sample and
number of hospitals included reflect the general popula-
tion of eCOPD patients evaluated in EDs in Spain. The
decision tree uses measures generally gathered by physi-
cians in the evaluation of eCOPD patients, and allows
clinicians to easily establish prognosis without having to
memorize the scores of different variables. It is much
easier to use than complex and often cumbersome
models. A similar CART model has been developed to
evaluate the long-term (5 year) prognosis of patients
with stable COPD. [5] Finally, our study points out an
important issue as it is that mortality after 30 days after
an ED visit is importantly conditioned by the comorbidi-
ties of the patient. This is important when planning the
care and follow up of these patients.
Limitations of our study must also be noted. First, did
not identify the causes of mortality. This could be im-
portant because cardiac events frequently occur after an
eCOPD and could be related to previous cardiac disease
rather than the eCOPD. The main limitation of decision
tree models is that including higher-order interactions
without considering the main effects could lead to spuri-
ous relations between predictors and overestimate the
effect of some predictors. This is sometimes referred to
as estimation bias. However, we believe that the use of
combined split and bootstrap validation techniques pro-
vides internally and externally validated results that
minimize spurious relations, as has been shown in previous
studies [6]. Our tree is proposed to be used at the ED, or
even before at the primary care level when seeing a eCOPD
patient, as a decision making tool. Nevertheless, since our
algorithm include either admitted to the hospital and
discharge to home patients a bias should be taken into ac-
count since more fatalities were obviously found among
patients admitted to the hospital. Therefore, caution must
be taken if the algorithm is used exclusively with patients
already admitted or discharged home. As an additional
limitation of the study we must include that no inter or
intra observer reliability studies were performed. Neverthe-
less, reviewers were trained by the principal investigators at
each site and were provided with a manual for the collec-
tion of data.
Conclusions
In summary, a CART model based on measures commonly
collected in the ED evaluation of patients experiencing an
eCOPD created a simple decision tree that identifies pa-
tients’ risk of short-term (30/60-day) mortality. Use of this
decision could provide valuable information about the
appropriate clinical care for these patients.
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